Progenity to Report Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update
16 Março 2022 - 5:23PM
Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating
in the field of oral biotherapeutics for gastrointestinal health
and beyond, today announced that it will report financial results
for the fourth quarter and full year ended December 31, 2021 on
Monday, March 28, 2022 after the close of financial markets.
Progenity’s management will host a webcast and conference call at
4:30 p.m. Eastern / 1:30 p.m. Pacific that day to discuss the
financial results and provide a corporate update.
The live call may be accessed by dialing 877-423-9813 for
domestic callers or 201-689-8573 for international callers and
entering the conference code: 13727360. A live webcast will be
available online in the Investor Relations section of the company
website at www.progenity.com and a replay will be available online
for 60 days following the call.
About Progenity
Progenity, Inc. is a biotechnology company innovating in the
fields of oral biotherapeutics, gastrointestinal health, and
women’s health. Progenity applies a multi-omics approach, combining
genomics, epigenomics, proteomics, and metabolomics to its
molecular testing products and to the development of a suite of
investigational ingestible devices designed to provide precise
diagnostic sampling and drug delivery solutions. Progenity’s vision
is to transform healthcare to become more precise and personal by
improving diagnoses of disease and improving patient outcomes
through localized treatment with targeted therapies.
For more information visit www.progenity.com, or follow the
company on LinkedIn or Twitter.
Investor ContactChuck PadalaManaging Director,
LifeSci Advisorsir@progenity.com (917) 741-7792
Media ContactKristin SchaefferCG
Lifemedia@progenity.com (858) 457-2436
Biora Therapeutics (NASDAQ:PROG)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Biora Therapeutics (NASDAQ:PROG)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Biora Therapeutics Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de